Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
In this trial we will investigate how this three-drug regimen may be improved, both with
respect to efficacy and toxicity, by making some modifications in the dosing and schedule in
the treatment of patients with hormone refractory prostate cancer.